Current and future options for the management of phantom-limb pain

Helena Knotkova¹,²
Ricardo A Cruciani¹–³
Volker M Tronnier⁴
Dirk Rasche⁴

¹Department of Pain Medicine and Palliative Care, Research Division, Institute for Non-invasive Brain Stimulation, Beth Israel Medical Center, New York, NY, USA; ²Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA; ³Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, NY, USA; ⁴Department of Neurosurgery, University of Lübeck, Germany

Abstract: Phantom-limb pain (PLP) belongs among difficult-to-treat chronic pain syndromes. Treatment options for PLP are to a large degree implicated by the level of understanding the mechanisms and nature of PLP. Research and clinical findings acknowledge the neuropathic nature of PLP and also suggest that both peripheral as well as central mechanisms, including neuroplastic changes in central nervous system, can contribute to PLP. Neuroimaging studies in PLP have indicated a relation between PLP and the neuroplastic changes. Further, it has been shown that the pathological neuroplastic changes could be reverted, and there is a parallel between an improvement (reversal) of the neuroplastic changes in PLP and pain relief. These findings facilitated explorations of novel neuromodulatory treatment strategies, adding to the variety of treatment approaches in PLP. Overall, available treatment options in PLP include pharmacological treatment, supportive non-pharmacological non-invasive strategies (e.g., neuromodulation using transcranial magnetic stimulation, visual feedback therapy, or motor imagery; peripheral transcutaneous electrical nerve stimulation, physical therapy, reflexology, or various psychotherapeutic approaches), and invasive treatment strategies (e.g., surgical destructive procedures, nerve blocks, or invasive neuromodulation using deep brain stimulation, motor cortex stimulation, or spinal cord stimulation). Venues of further development in PLP management include a technological and methodological improvement of existing treatment methods, an implementation of new techniques and products, and a development of new treatment approaches.

Keywords: phantom-limb pain (PLP), neuropathic pain, non-invasive treatment, invasive treatment, neuromodulation

Introduction

It is estimated that more than 80% of patients with partial or total loss of a limb develop chronic phantom-limb pain (PLP), i.e., pain that seems to be located in the missing limb.¹ For the purposes of clinical assessment and treatment, it is important to differentiate PLP from other amputation-related phenomena, such as stump-pain, (i.e., pain in the remaining part of the limb);² non-painful phantom-limb sensation, or telescoping, i.e., sensation when the distal part of the phantom is gradually felt to approach the residual limb and may even be experienced within the stump.³ Risks factors for PLP⁴–⁶ include gender (PLP being more common in women), upper extremity amputation, presence of pre-amputation pain, residual pain in remaining limb, or time after amputation (there are reports of a two-peak period of onset, the first within a month after amputation and the second after 1 year).⁷ Further, stress, anxiety, depression, and other emotional triggers also highly likely contribute to PLP.⁷ Recommended preventive measures...
include using preemptive and postoperative perineural or epidural local anesthetics, intraoperative precautions related to protection of the peripheral nerves, and importance of early rehabilitation.9,10

Treatment options for PLP are, to a large degree, implicated by the level of understanding the mechanisms and nature of PLP. In a historical perspective, PLP had been considered mostly of psychological origin, with the prevalent belief that PLP was generated “in the patient’s head.” However, the development of advanced diagnostic methods, recently including neuroimaging, has facilitated explorations of changes in peripheral and central neural networks after amputation and their putative contribution to the development of PLP.11-13 The findings acknowledged the neuropathic nature of PLP and also suggested that both peripheral, as well as central mechanisms, including neuroplastic changes in central nervous system, can contribute to PLP.14,15 In periphery, axotomized afferent neurons may develop retrograde degeneration and shrinking that primarily involves unmyelinated neurons, and local changes at the site of the remaining nerve endings may contribute to the development of enhanced sensitivity of the afferent fibers.16 Further, a sprouting of injured axon can lead to formation of neuromas in the residual limb. Neuromas show abnormal sensitivity to mechanical and chemical stimuli and can be a source of abnormal ectopic discharges.16,17 Besides neuromas, dorsal root ganglia have also been shown to generate the discharge of ectopic activity,18 substantially increasing the overall barrage of abnormal afferent input to the spinal cord and upper centers, such as the brainstem, thalamus, or cortex. Further, post-amputation changes at the level of the spinal cord include formation of new neural connections between the axonal sprouts from the proximal part of the amputated nerve and spinal cord neurons, which contributes to sensitization of pain-transmission neurons. The sensitization may manifest itself as mechanical hyperalgesia and an expansion of peripheral receptive fields,19 and is linked to an increase of activity on NMDA receptors mediated for example by substance P, neurokinins, and tachykinins at the dorsal horns of the spinal cord.20 There also may be a reduction in the local intersegmental inhibitory mechanisms, resulting in spinal disinhibition and enhanced nociceptive input to the supraspinal centers. Interestingly, a pathologic change of the afferent input (whether it is an increase or decrease) represents a significant source of neural plasticity, ie, dynamic changes in the function of neurons and neural networks in the central nervous system, including both spinal and cerebral parts of the Pain Matrix, the pain processing network.18,21 Neuroplastic alterations at the level of the brain include changes in neuronal excitability, changes in the somatotopic organization in the cortical and subcortical areas (eg, in the somatosensory and motor cortices or in thalamus), and structural changes (thickening or thinning) of neuronal layers. Indeed, neuroimaging studies in PLP have shown presence of such neuroplastic changes in amputees and the relation to the presence of PLP.11-13,22-25 Further, it has been shown that the pathological neuroplastic changes can be reverted and that an improvement (reversal) of the neuroplastic changes in PLP patients was paralleled by pain relief.13 These findings facilitated explorations of novel neuromodulatory treatment strategies, such as transcranial magnetic stimulation (TMS) or motor imagery, adding to the variety of treatment approaches in PLP.

Overall, treatment options in PLP include pharmacological treatment, supportive non-pharmacological non-invasive strategies, and invasive treatments.

Pharmacological treatment
The pharmacological armamentarium is vast,26-49 (Table 1), but efficacy of most of the drugs utilized to treat PLP have not been determined from PLP controlled trials, but rather extrapolated from positive results obtained on a variety of other neuropathic pain syndromes (eg, painful polyneuropathy [PPN] or post-herpetic neuralgia [PHN]).

Acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs)
A cross-sectional study found acetaminophen and NSAIDs to be the most common medications used in PLP.4 This widely-used over-the-counter medication has relatively little anti-inflammatory activity as compared to NSAIDs. However, acetaminophen and other NSAIDs all act by the same mechanism (inhibition of prostaglandin synthesis) and all show varying levels of analgesic, anti-inflammatory, anti-pyretic, and antiplatelet actions, and decrease the nociception at peripheral and central level.28

Antidepressants
Antidepressants have been utilized for the management of neuropathic pain since the eighties after work by Mitchel Max showed analgesic effect by amitriptyline independent of improvement of depression. Since then many drugs have been added to the list (Table 1), with different degrees of success.26,29,30

Tricyclics are on top of the list for their efficacy for the management of neuropathic pain syndromes, but the results
Table 1 Level of evidence for the drugs utilized to treat phantom-limb pain and other neuropathic-pain conditions

<table>
<thead>
<tr>
<th>Drug</th>
<th>PLP</th>
<th>PPN</th>
<th>PHN</th>
<th>TN</th>
<th>HIV</th>
<th>CP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen</td>
<td>CrS/P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSAIDs</td>
<td>CrS/P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antidepressants tricyclics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>CT/P/N</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td>CT/N</td>
<td>CT&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Desipramine</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imipramine</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clomipramine</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trazadone</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maprotiline</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetracyclics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>CS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSRIs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Escitalopram</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paroxetine</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sertraline</td>
<td>OLT/P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bupropion</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SNRIs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duloxetine</td>
<td>CR</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venlafaxine ER</td>
<td>CT/N</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Milnacipran</td>
<td>CR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anticonvulsants calcium channel alpha 2 delta ligands</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gabapentin</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CR</td>
<td>CT/N</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CR</td>
<td>CT/N</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Topiramate</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valproate</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium channel blockers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bupivacaine (inject)</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lidocaine</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infusion</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patches</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexiletine</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NMDA receptor antagonists</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Memantine</td>
<td>CR/P/N&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ketamine&lt;sup&gt;c&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dextromethorphan</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NMDA+Potassium channel blocker</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flupirtine (plus opioids)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opioids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methadone</td>
<td>CS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buprenorphine&lt;sup&gt;d&lt;/sup&gt;</td>
<td>CR/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxycodone</td>
<td>CR/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levorphanol</td>
<td>CT(M)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tramadol</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscle relaxants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baclofen</td>
<td>CR&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzo diazepines</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clonazepam</td>
<td>CS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diazepam</td>
<td>CT/P&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
for the management of PLP are mixed. Due to the availability of newer agents with similar efficacy and better profile of side effects the tricyclics have been less utilized in the last few years. The anticholinergic effect presented by these drugs is responsible for the major side effects including sedation, constipation, urinary retention, and electrical conduction changes that made them potentially problematic in the elderly. Sometimes the side effects can help to manage comorbidities and a night dose of amitriptyline might be preferable for patients with insomnia. The serotonin-norepinephrine reuptake inhibitors (SNRIs) are antidepressants that block the reuptake of serotonin and norepinephrine (eg, duloxetine) and although they have become popular due to a better profile of side effects and similar good efficacy for neuropathic pain, migraines, and fibromyalgia, the level of evidence for the management of PLP is low (Table 1). Milnacipran, in the United States, has been approved for the management of fibromyalgia, but although the level of evidence to treat PLP is low, there are studies that show benefit in neuropathic pain.31 Agents with a preferentially dopaminergic mechanism of action like bupropion have also been shown to be beneficial for the management of neuropathic pain. The selective serotonin reuptake inhibitors (SSRIs) are considerd to be less effective but there are positive controlled trials in PPN for escitalopram, fluoxetine, and paroxetine (Table 1).26

Anticonvulsants
Some anticonvulsants, like gabapentin and pregabalin, have been shown to be efficacious for the treatment of PLP in controlled trials.26,32,33 The list grows when the evidence of efficacy is looked at on other types of neuropathic pain like painful peripheral neuropathy and post-herpetic neuralgia and includes gabapentin, pregabalin, carbamazepine, lamotrigine, phenytoin, topiramate, and valproate (Table 1). Pain with neuralgic characteristics that can occur at the level of the stump, can be successfully treated with the older agents like carbamazepine or the newer oxcarbazepine.

Sodium channel blockers
Sodium channel blockers can be administered orally, intravenously, epidurally, or intrathecally. The evidence that supports its use varies with the agent and the formulation. The only controlled trial that supports its use for PLP is with injectable bupivacaine. A study with lidocaine infusion was negative for PLP and another positive for PPN, while there are no positive trials for the oral formulation mexiletine (Table 1).29

NMDA receptor antagonists
Intravenous infusion of ketamine, an NMDA receptor antagonist, has been shown to be beneficial for PLP but other agents of this family have not been consistently shown to be efficacious. More recently it has been utilized to manage pain that does not respond to other agents as a single intravenous infusion or repetitive infusions as outpatient. Many clinicians treat patients that experience at least 50% pain reduction with the infusion, with oral ketamine that can be compounded.26 The long term use is in many occasions not possible due to side effects. There are mixed case reports with memantine, another NMDA antagonist that was developed for the management of dementia in Alzheimer’s disease, for PLP and positive and negative control trials for other forms of neuropathic pain. There are positive control trials with dextromethorphan for PPN and a negative trial for PHN.

Opioids
Morphine has been shown to be beneficial for the management of PLP in a controlled trial and there is case series showing analgesia with methadone and a case report with buprenorphine reporting analgesia.29,38 In addition morphine,
oxycodone, levorphanol, and methadone are efficacious for the management of other forms of neuropathic pain including PPN and PHN. The long term use of these drugs has been questioned due to the scarce evidence of long term benefits including function. Concerns about addiction, diversion, and side effects including decrease in testosterone level have also been raised. Despite this, the use of opioids for the management of neuropathic pain has been supported in several guidelines including the American Pain Society (APS) and the American Academy of Pain Medicine (AAPM). Methadone has received a differential treatment due to the additional concern about cardiac toxicity and the Canadian guidelines place it at a lower step than the other opioids.

**Tramadol**

There are positive clinical trials with tramadol supporting its use for the management of PLP and other forms of neuropathic pain including PPN and PHN.1 Tramadol is an agent with a mixed mechanism of action that includes low affinity for the mu opioid receptors and the ability to blockade the reuptake of norepinepine and serotonin. It can also produce physical dependency but it is Schedule 3 and this is one of the reasons why it is popular among prescribers.

**Others**

There are other drugs that have been utilized with variable degree of success, including muscle relaxants like baclofen, the centrally acting benzodiazepines, and the corticosteroids. There is a case report for baclofen in PLP that reports benefit, a positive controlled trial in PHN, a positive controlled trial for diazepam, and an open label trial for alprazolam for the management of PPN. There are case series that report benefit with corticosteroids like prednisone dexamethasone for PPN. Capsaicin has been utilized for neuropathic pain with variable success for many years, which has not been very popular due to the pain that occurs after its application. There is a new formulation in a patch form that seems to be promising, although there is no data available yet for PLP (Table 1).

In summary, there is a limited number of control studies done specifically to assess drug efficacy in PLP.26 The ones showing significant beneficial effect include trials with amitriptyline,30 gabapentin,32 tramadol,40 and morphine.33 There are also some case reports/series with mirtazapine,41 duloxetine,33 milnacipran,31 memantine,34,35 baclofen,36 buprenorphine,37 and methadone,38 that suggest beneficial effects on PLP. The selection of the agent should be based on the current understanding of PLP as a neuropathic type of condition. Hence, in addition to drugs that show efficacy in PLP, other drugs with efficacy in other types of neuropathic pain could be prescribed.38 However, the drug selection should take into consideration the clinical presentation of the PLP syndrome. PLP is continuous, intense, sometimes burning and for that reason a drug with efficacy in PPN or PHN may be chosen. Further, as a neuralgic type of pain may be present in PLP (possibly a result of a neuroma formation in the stump), drugs efficacious in neuralgic type of pain, like carbamazepine or oxcarbamazepine, can be added to the regimen. A trial in every patient should include appropriate titration of the drug up to levels where efficacy has been shown in other neuropathic conditions, for at least 4–6 weeks. Thus, completion of an appropriate trial usually takes 1–2 months.39

It has been proposed that the administration of analgesic and anesthetics prior to a surgical intervention4,42 and intraoperative precautions with the handling of peripheral nerves and not to ligate with sutures, could prevent the development of central sensitization due to impulses generated at the level of the amputation, however the results have been mixed. Epidural analgesia, ropivacaine, and patient controlled analgesia during the perioperative period have shown to decrease PLP, but ketamine and ketamine plus bupivacaine showed conflicting results.4,44,45

As PLP is often of severe intensity, causing a long-lasting and debilitating decrease of quality of life in many amputees,48 pharmacological treatment itself in many patients does not provide sufficient pain relief. Therefore, supportive treatments may enhance the treatment regimen.

**Supportive non-invasive treatment approaches**

**Non-invasive neuromodulation**

Several approaches are available within non-invasive neuromodulation in PLP, for example repetitive transcranial magnetic stimulation (rTMS), visual feedback (mirror-box therapy), or motor imagery.

**Transcranial magnetic stimulation (TMS)**

TMS exerts its effects on brain structures via electrical currents induced by a powerful magnetic field delivered with a magnetic coil over the scalp.49 It can be delivered as a single pulse or as sets of pulses (rTMS). Several studies have shown that a single session of rTMS can transiently relieve pain in some patients with chronic neuropathic pain,30–34 and a multiple application on several consecutive days can lead to prolongation of the effects.55,56 However, results from rTMS...
treatment specifically in patients with PLP are anecdotal, based on case-reports but not sham-controlled trials, and therefore not conclusive.55–57 Although the application of rTMS in PLP patients resulted in pain relief,55–57 short-term durability of the effects is a significant issue limiting clinical use of this treatment.

Visual feedback therapy and motor imagery
Both the visual feedback therapy (mirror-box therapy) and motor imagery are based on behaviorally relevant sensory-motor stimulation of the stump.58–62 A rationale of this approach arises from the existence of maladaptive neuroplastic changes underlying PLP, specifically cortical reorganization in the somatosensory and motor cortices, a relation between the cortical reorganization and the occurrence of PLP, and beneficial effects of cortical normalization on PLP.

The treatment using visual feedback emerged from the observation that looking at the reflection of an intact limb in a mirror box can induce sensations of movement in the phantom limb.59–65 Motor imagery is based on percepts or sensations generated internally by the brain, a mental representation of an actual sensation or movement.58 Physiological studies have shown that both the mirror-box therapy and the motor imagery resulted in increased excitability of the corticospinal pathways.64 This at least partially depends on the so-called mirror-neuron system61 which includes neurons that are active not only during the execution of the task itself but also during the observation of the task. This finding provides support for the idea that imagined movements share the same cortical pathways as executed motor tasks. Further, it has been shown that visual feedback actually dominates somatosensory feedback and sensory experiences can be evoked by visual information alone, and it has been shown that the visual system enhances tactile sensitivity.61,65

Both the mirror therapy and the motor imagery can be very beneficial in PLP patients.58,60,62,63,66–68 As an example, a controlled neuroimaging study of motor imagery in PLP58 showed evidence of cortical reorganization of motor and somatosensory cortices and its correlation with patients’ pain scores prior to the motor imagery training. The training resulted in a significant decrease of intensity and unpleasantness of pain which correlated with reduction (improvement) of cortical reorganization.

Overall, the mirror-box therapy and motor imagery are safe and non-expensive additions to the PLP treatment options.

Other supportive non-invasive therapies
There is preliminary evidence that PLP patients may benefit from other non-invasive supportive treatments, such as physical therapy including the stump and phantom limb, reflexology or hypnosis,69,70 or peripheral transcutaneous electrical nerve stimulation of the affected limb.71 Although there are multiple reports of transcutaneous electrical nerve stimulation use in PLP, a recent systematic review72 revealed lack of evidence from randomized controlled trials on which effectiveness of transcutaneous electrical nerve stimulation for PLP could be judged.

Further, a use of myoelectric prosthesis may improve PLP.73,74 Research of stimulation-induced neural plasticity indicate that extensive behaviorally relevant stimulation of the affected part of the body leads to an expansion of its representation zone, and an intensive use of a myoelectric prosthesis has been shown to be positively linked to decreased PLP as well as decreased degree of cortical reorganization.75

Another venue of non-invasive support to PLP patients includes various psychotherapeutic approaches.76

Invasive treatment strategies
Surgical destructive interventions and nerve blocks
Because of a high rate of refractory chronic pain among PLP patients with failed non-invasive treatments, all kinds of invasive procedures were performed in the history of those cases.77–93 Destructive procedures like thermal nerve root destruction, rhizotomy, spinal ganglionectomy, and also dorsal root entry zone lesion have been performed.81–93 As per their nature, most of these procedures led to unrestorable damage of nervous tissue and functions. Initial results with high rates of pain relief were accompanied with a high rate of complications and followed by a high rate of recurrent pain and therefore yielding disappointing long term results after several months. Nowadays, the indication for destructive procedures is limited only to a few diagnoses for severe, refractory pain patients with short life expectancy. The dorsal root entry zone lesion is the only destructive procedure for selected patients with deafferentation pain and brachial plexus avulsion or cervical nerve root injury. In total, numbers of destructive procedures are decreasing year by year.

Non-destructive interventions such as nerve blocks have also been used in the PLP treatment. For example, interscalene blocks or stellate ganglion blocks for upper extremity PLP, or lumbar sympathetic blocks for lower extremity PLP can lead to decrease of PLP.95 These blocks are often combined with physical therapy.
Invasive neuromodulation

Invasive neuromodulation is considered the last-resort treatment for patients who failed various trials of non-invasive treatments. On contrary to surgical destructive procedures, neuromodulatory techniques are PLP-mechanisms-driven, specifically addressing maladaptive central neuroplastic changes in the Pain Matrix (brain pain-processing networks).

Deep brain stimulation (DBS)

DBS is an electrical stimulation performed after stereotactic implantation of thin stick leads into subcortical areas such as the thalamus or basal ganglia. In the early 1950s, the first clinicians used thalamic stimulation to treat chronic pain patients. Since these first clinical applications a lot of case series, retrospective patient samples, and reviews were published. A recent review lists a total of 600 patients with DBS due to different chronic pain syndromes. Evidence up to date suggests that the significance of DBS for PLP is controversial. However, some patients clearly benefit from DBS, experiencing long term pain relief >25% and improved quality of life.

Motor cortex stimulation (MCS)

MCS (Figure 1) is an electrical stimulation of the precentral gyrus using epidural surgical leads and subthreshold stimulation. Historically, after the application of MCS in patients with post-stroke-pain or trigeminal neuropathic pain, also patients with PLP became candidates for the MCS treatment. Some centers perform a direct implantation of the neurostimulator in the subcutaneous tissue (infraclavicular or abdominal), while others perform also a postoperative testing with externalized extensions of the lead and an external stimulation. Such a testing phase allows for a placebo double-blinded stimulation period, so that false positive responders can be identified. It has been suggested that the definite implantation of neurostimulator would be performed only in patients with a positive effect of the real MCS and a pain reduction of >30%, and the subjective impression of pain improvement by the patient. Information from different centers and experts show that PLP is an accepted indication for MCS. PLP yields favorable results in about 53% of PLP patients.

Spinal cord stimulation (SCS)

SCS involves the placement of electrodes in the epidural space adjacent to the spinal area presumed to be the source of pain. An electric current is then applied to achieve sympathectolytic and other neuromodulatory effects. Typically, the first phase of treatment involves the temporary placement of an electrical stimulator. Patients are monitored over a period of time to determine the pain reduction. Only patients positively responding to the stimulation would be considered for a permanent implantation. Clinical results indicate beneficial effects of SCS in PLP patients on immediate as well as long term outcomes, although the percentage of benefiting patients declined with time. For example, good results have been observed at 2 year follow-up in 52.4% of 64 PLP patients, that decreased to 39% at 5 year follow-up. However, given the fact that PLP is a difficult-to-treat pain syndrome and many PLP patients do not respond to other treatment strategies, SCS represents a promising treatment option for selected subpopulation of patients. Similarly to other invasive treatments, such as MCS or DBS, SCS is also reserved for patients that had not benefited from non-invasive treatment strategies.

Conclusions and future directions

Although some of the currently available therapies yield promising results, many PLP patients still remain without satisfactory pain relief. Therefore, continual advances in the PLP treatment are of high importance. It can be anticipated...
that pain management in PLP patients may in the future benefit from the following venues:

- Technological and methodological improvement of existing treatment methods.

Improved formulations of pharmacological agents, such as long-acting formulations or new routes of applications, may improve pain relief and overall quality of life in patients with PLP. Further, as discussed in other sections of this article, efficacy of various neuropathic-pain medications has not yet been established for PLP. Establishing the drug efficacy specifically for PLP can certainly facilitate a patient-tailored selection of more-benefiting pharmacological regimens for PLP patients.

Further, it is anticipated that an improvement of invasive DBS and MCS treatments will be facilitated by technological advances of imaging techniques, as higher resolution would provide more accurate information about the relevant brain structures. Furthermore, technological advances in the detection of pain-related electrical signals in the brain or at its surface would enable more specific and target-oriented DBS and MCS.

- Implementation of new methods and products within current PLP treatment-strategies.

Besides the fast progress of the pharmaceutical industry and implementation of new agents, also non-pharmacological treatment strategies in PLP may enrich their repertoire of available methods. For example, within the non-invasive neuromodulatory strategy, transcranial direct current stimulation has recently shown promising clinical potential in some neuropathic pain syndromes, may be in the future explored in the treatment of PLP. As transcranial direct current stimulation yielded pain relief in various patient-populations (eg, patients with fibromyalgia, Parkinson’s disease, pelvic pain, central pain due to spinal cord injuries), it can be anticipated that PLP patients as well may benefit from this method. Further, a wider implementation of the use of myoelectric prosthesis in clinical practice may enrich PLP management in the future. Behaviorally relevant stimulation of the stump delivered via myoelectric prosthesis addresses cortical reorganization has been identified among pathological mechanisms underlying PLP.

- Development of new treatment approaches.

Pain research incorporating new perspectives, such as genetics and epi-genetics, provides an exciting opportunity to enhance the insight into the mechanisms and development of chronic pain syndromes, including PLP, and to provide an evidence base for the development of novel treatment approaches and targets. For example, recent studies indicate that gene CACNG2, which is expressed in the peripheral and central nervous system and encodes neuroprotein stargazin, may be implicated in the development neuropathic pain. If confirmed by future studies, the gene may be of high significance for PLP. Understanding genetic and epigenetic factors (ie, functionally relevant modifications to the genome that do not involve a change in the nucleotide sequence) in the development of PLP may lead to exploration of epigenetic pharmaceuticals for this difficult-to-treat condition, as recently witnessed in other areas of medicine, for example in oncology.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


Knotkova et al


